Voorbeelden van het gebruik van Saquinavir in het Engels en hun vertalingen in het Nederlands
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Co-administration with saquinavir.
Saquinavir concentrations may be increased.
The active substance is saquinavir.
Monitoring for saquinavir toxicity recommended.
Mesilate corresponding to 200 mg saquinavir.
Mean± SD Saquinavir(%CV) Pharmacokinetic Parameters.
Zalcitabine and/ or Zidovudine unboosted saquinavir.
Saquinavir is essentially completely metabolised by CYP3A4.
Grapefruit juice(single dose) unboosted saquinavir.
Atazanavir, saquinavir used to treat HIV infection.
Invirase is a medicine containing the active substance saquinavir.
Sildenafil had no effect on saquinavir pharmacokinetics.
Saquinavir should only be given in combination with ritonavir.
may decrease saquinavir concentrations.
Number of Saquinavir Associated Resistance Mutations at Baseline.
Dronedarone(for atrial fibrillation) saquinavir anti-HIV treatment.
Saquinavir partitions extensively into the tissues.
The pharmacokinetics of saquinavir is stable during long-term treatment.
Saquinavir may be less effective in patients taking dexamethasone.
Distribution in adults: Saquinavir partitions extensively into the tissues.
Saquinavir↔ Ritonavir↓ effectiveness as boosting agent not modified.
only limited information on the safety and efficacy of unboosted saquinavir is available for patients suffering from chronic diarrhoea or malabsorption.
Saquinavir, the first protease inhibitor to seek approval. To take a closer look at D.
Absorption: In HIV-infected adult patients, Invirase in combination with ritonavir at doses of 1000/100 mg twice daily provides saquinavir systemic exposures over a 24-hour period similar to
Saquinavir/ritonavir and Nevirapine Teva can be co- administered without dose adjustments.
Each capsule contains saquinavir mesilate corresponding to 200 mg saquinavir.
Following intravenous administration 66% of circulating saquinavir was present as unchanged compound
only limited information on the safety and efficacy of unboosted saquinavir is available for patients suffering from chronic diarrhoea or malabsorption.
Monitoring of saquinavir plasma concentration is recommended see section 4.4.